{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:16:29Z","timestamp":1793038589412,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Single-agent immunotherapy is currently the recommended second-line therapy for patients with advanced non\u2013small cell lung cancer (NSCLC) without targetable mutations; however, the objective response rate (ORR) remains low. This phase II study evaluated the efficacy of the combination therapy of sintilimab plus docetaxel and explored potential biomarkers for efficacy prediction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty patients with NSCLC without targetable mutations whose disease progressed from first-line platinum-based chemotherapy from October 2019 to December 2020 were enrolled in this single-arm, single-center, phase II trial. Sintilimab (200\u2009mg) and docetaxel (75\u2009mg\/m<jats:sup>2<\/jats:sup>) were administered every 3\u2009weeks until progression. The primary endpoint was ORR. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Biomarker analyses of blood and tissue samples were also performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 30 patients, 11 patients had partial response, resulting in an ORR of 36.7%. The median PFS was 5.0\u2009months (95%CI: 3.9\u20136.1) and OS was 13.4\u2009months (95%CI: 5.6\u201321.2). The most common immune-related adverse event of any grade was hepatitis, observed in 23.3% (7\/30) of patients. Treatment-emergent adverse events were manageable. Patients detected with high PD-L1 expression in circulating tumor cells (cutoff value \u226532.5% based on the median CTC-PD-L1 expression) achieved significantly higher ORR (60% versus 13.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.021) and significantly longer median PFS (6.0 versus 3.5\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.011) and median OS (15.8 versus 9.0\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.038) than those with low CTC-PD-L1 level. Patients detected with PD-L1\u2009&lt;\u20091% and CD8\u2009\u2265\u20091% expression from their baseline tissue samples had significantly higher ORR (83.3% versus 12.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.026) but similar PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.62) and OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.15).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrated the effectiveness and safety of sintilimab plus docetaxel as a second-line treatment of NSCLC without targetable mutations after progression from first-line platinum-based chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was registered in the Clinical trials registry with ClinicalTrials.gov Identifier NCT03798743 (SUCCESS).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10045-0","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T15:03:04Z","timestamp":1662390184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yongchang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"10045_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki NK, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19:9\u201331.","journal-title":"Nat Rev Cancer"},{"key":"10045_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-015-1768-3","volume":"65","author":"P Muller","year":"2016","unstructured":"Muller P, et al. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother. 2016;65:1\u201311.","journal-title":"Cancer Immunol Immunother"},{"key":"10045_CR3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong HT, Restifo NP. Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat Immunol. 2002;3:999\u20131005.","journal-title":"Nat Immunol"},{"key":"10045_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"10045_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","volume":"11","author":"J Wang","year":"2019","unstructured":"Wang J, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019;11:1443\u201351.","journal-title":"MAbs"},{"key":"10045_CR6","doi-asserted-by":"publisher","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Mai W, Jiang W, Geng Q. sintilimab: a promising anti-tumor PD-1 antibody. Front Oncol. 2020;10:594558.","journal-title":"Front Oncol"},{"key":"10045_CR7","doi-asserted-by":"publisher","first-page":"e15125","DOI":"10.1200\/JCO.2018.36.15_suppl.e15125","volume":"36","author":"J-M Xu","year":"2018","unstructured":"Xu J-M, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. J Clin Oncol. 2018;36:e15125.","journal-title":"J Clin Oncol"},{"key":"10045_CR8","doi-asserted-by":"publisher","first-page":"102731","DOI":"10.1016\/j.ebiom.2020.102731","volume":"54","author":"Y Shi","year":"2020","unstructured":"Shi Y, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine. 2020;54:102731.","journal-title":"EBioMedicine"},{"key":"10045_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Sintilimab: First global approval. Drugs. 2019;79:341\u20136.","journal-title":"Drugs"},{"key":"10045_CR10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, et al. Efficacy and safety of Sintilimab plus Pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15:1636\u201346.","journal-title":"J Thorac Oncol"},{"key":"10045_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang Y, et al. Updated overall survival data and predictive biomarkers of Sintilimab plus Pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol. 2021;16:2109\u201320.","journal-title":"J Thorac Oncol"},{"key":"10045_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"10045_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39\u201351.","journal-title":"J Thorac Oncol"},{"key":"10045_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193\u2013203.","journal-title":"Chest"},{"key":"10045_CR15","doi-asserted-by":"crossref","unstructured":"Basch E, et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).\u00a0J Natl Cancer Inst. 2014;106(9):dju244.","DOI":"10.1093\/jnci\/dju244"},{"key":"10045_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu H, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 Axis. Cancer Cell. 2020;37:324\u2013339 e328.","journal-title":"Cancer Cell"},{"key":"10045_CR17","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet"},{"key":"10045_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"10045_CR19","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer version 5.2021. National Comprehensive Cancer Network (NCCN); 2021. www.nccn.org."},{"key":"10045_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16:1501\u201311.","journal-title":"J Thorac Oncol"},{"key":"10045_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709\u201317.","journal-title":"JAMA Oncol"},{"key":"10045_CR22","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","volume":"16","author":"S Lu","year":"2021","unstructured":"Lu S, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16:1512\u201322.","journal-title":"J Thorac Oncol"},{"key":"10045_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol. 2022;17:544\u201357.","journal-title":"J Thorac Oncol"},{"key":"10045_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9:305\u201314.","journal-title":"Lancet Respir Med"},{"key":"10045_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"10045_CR26","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"10045_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723\u201333.","journal-title":"J Clin Oncol"},{"key":"10045_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2005.37.6.339","volume":"37","author":"BY Shim","year":"2005","unstructured":"Shim BY, et al. The safety and efficacy of second-line single docetaxel (75 mg\/m (2)) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy. Cancer Res Treat. 2005;37:339\u201343.","journal-title":"Cancer Res Treat"},{"key":"10045_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2020.0409","volume":"6","author":"O Arrieta","year":"2020","unstructured":"Arrieta O, et al. Efficacy and safety of Pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol. 2020;6:856\u201364.","journal-title":"JAMA Oncol"},{"key":"10045_CR30","doi-asserted-by":"crossref","unstructured":"Han X, et al. Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.\u00a0J Cancer Res Clin Oncol. 2022:1\u20139.","DOI":"10.1007\/s00432-022-04023-z"},{"key":"10045_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41379-021-00932-5","volume":"35","author":"LM Sholl","year":"2022","unstructured":"Sholl LM. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Mod Pathol. 2022;35:66\u201374.","journal-title":"Mod Pathol"},{"key":"10045_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2017.01.004","volume":"75","author":"S Kim","year":"2017","unstructured":"Kim S, et al. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. Eur J Cancer. 2017;75:141\u20139.","journal-title":"Eur J Cancer"},{"key":"10045_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12967-020-02636-x","volume":"18","author":"XL Wei","year":"2020","unstructured":"Wei XL, et al. PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. J Transl Med. 2020;18:475.","journal-title":"J Transl Med"},{"key":"10045_CR34","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/onc.2015.192","volume":"35","author":"K Pantel","year":"2016","unstructured":"Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216\u201324.","journal-title":"Oncogene"},{"key":"10045_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.CD-19-0384","volume":"10","author":"R Klotz","year":"2020","unstructured":"Klotz R, et al. Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers. Cancer Discov. 2020;10:86\u2013103.","journal-title":"Cancer Discov"},{"key":"10045_CR36","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/clinchem\/hvab131","volume":"67","author":"L Sinoquet","year":"2021","unstructured":"Sinoquet L, et al. Programmed cell death ligand 1-expressing circulating tumor cells: a new prognostic biomarker in non-small cell lung Cancer. Clin Chem. 2021;67:1503\u201312.","journal-title":"Clin Chem"},{"key":"10045_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cllc.2021.03.005","volume":"22","author":"FG Dall'Olio","year":"2021","unstructured":"Dall'Olio FG, et al. PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung Cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2021;22:423\u201331.","journal-title":"Clin Lung Cancer"},{"key":"10045_CR38","doi-asserted-by":"publisher","first-page":"e1438111","DOI":"10.1080\/2162402X.2018.1438111","volume":"7","author":"C Yue","year":"2018","unstructured":"Yue C, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 2018;7:e1438111.","journal-title":"Oncoimmunology"},{"key":"10045_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.mehy.2016.05.022","volume":"93","author":"X Wang","year":"2016","unstructured":"Wang X, et al. CTC immune escape mediated by PD-L1. Med Hypotheses. 2016;93:138\u20139.","journal-title":"Med Hypotheses"},{"key":"10045_CR40","doi-asserted-by":"publisher","first-page":"673042","DOI":"10.3389\/fmolb.2021.673042","volume":"8","author":"A Boisson","year":"2021","unstructured":"Boisson A, et al. Fluorescent multiplex immunohistochemistry coupled with other state-of-the-art techniques to systematically characterize the tumor immune microenvironment. Front Mol Biosci. 2021;8:673042.","journal-title":"Front Mol Biosci"},{"key":"10045_CR41","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","volume":"5","author":"S Lu","year":"2019","unstructured":"Lu S, et al. Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1195\u2013204.","journal-title":"JAMA Oncol"},{"key":"10045_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-022-02379-1","volume":"41","author":"D de Miguel-Perez","year":"2022","unstructured":"de Miguel-Perez D, et al. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022;41:186.","journal-title":"J Exp Clin Cancer Res"},{"key":"10045_CR43","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","volume":"28","author":"CY Mu","year":"2011","unstructured":"Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682\u20138.","journal-title":"Med Oncol"},{"key":"10045_CR44","first-page":"p1484","volume":"38","author":"JA Huang","year":"2011","unstructured":"Huang JA, Chen YB, Mu CY. PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: a 5-year-follow-up study. Eur Respir J. 2011;38:p1484.","journal-title":"Eur Respir J"},{"key":"10045_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.lungcan.2016.04.021","volume":"98","author":"M Shimoji","year":"2016","unstructured":"Shimoji M, et al. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer. 2016;98:69\u201375.","journal-title":"Lung Cancer"},{"key":"10045_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/atm.2017.08.04","volume":"5","author":"M Mathew","year":"2017","unstructured":"Mathew M, Safyan RA, Shu CA. PD-L1 as a biomarker in NSCLC: challenges and future directions. Ann Transl Med. 2017;5:6.","journal-title":"Ann Transl Med"},{"key":"10045_CR47","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139\u201345.","journal-title":"Cancer Res"},{"key":"10045_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.7150\/jca.26444","volume":"10","author":"Z Lin","year":"2019","unstructured":"Lin Z, et al. Deciphering microenvironment of NSCLC based on CD8+ TIL density and PD-1\/PD-L1 expression. J Cancer. 2019;10:211\u201322.","journal-title":"J Cancer"},{"key":"10045_CR49","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li F, et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine. 2021;41:101134.","journal-title":"EClinicalMedicine"},{"key":"10045_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665\u201373.","journal-title":"Lancet"},{"key":"10045_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143\u201355.","journal-title":"Lancet Oncol"},{"key":"10045_CR52","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jtho.2022.04.001","volume":"17","author":"J Lee","year":"2022","unstructured":"Lee J, et al. Bevacizumab plus Atezolizumab after progression on Atezolizumab monotherapy in pretreated patients with NSCLC: an open-label, two-stage, phase 2 trial. J Thorac Oncol. 2022;17:900\u20138.","journal-title":"J Thorac Oncol"},{"key":"10045_CR53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2217\/imt-2021-0196","volume":"14","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8(+) T cells in lung cancer. Immunotherapy. 2022;14:695\u2013708.","journal-title":"Immunotherapy"},{"key":"10045_CR54","doi-asserted-by":"crossref","unstructured":"Osta BE, et al. A phase 2 study of docetaxel, Ramucirumab, and Pembrolizumab for patients with metastatic or recurrent non-small-cell lung Cancer (NSCLC) who progressed on platinum-doublet and PD-1\/PD-L1 blockade. Clin Lung Cancer. 2022.","DOI":"10.1016\/j.cllc.2022.06.003"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10045-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10045-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10045-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T16:04:25Z","timestamp":1662393865000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10045-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10045"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10045-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Hunan Cancer Hospital Institutional Review Board Committee (2019YYQ -SSB-019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"952"}}